What Stilbestrol Treats: Main Uses and Benefits

Stilbestrol (Diethylstilbestrol) is a synthetic estrogen that is commonly used across key therapeutic domains.

Therapeutic Use and Benefits

This medication is applied in clinical settings defined by significant estrogen deficiency and within hormonal oncology. As part of symptomatic management, it assists in easing the overall symptom burden associated with advanced malignancies like progressive prostate cancer and metastatic breast cancer. It is also relevant for easing the symptoms related to physical discomfort of estrogen deficiency, including the intensity of disruptive symptoms related to heightened physiological activity (hot flashes), atrophic vaginitis, and vulvar dystrophy. Furthermore, Stilbestrol supports the body's hormonal balance in conditions resulting in the chronic absence of natural estrogen, such as female hypogonadism and post-surgical castration.

The use supports maintaining day-to-day comfort and stability during symptomatic periods. It is utilized for supporting the body's hormonal balance and general well-being in settings where hormonal support is relevant due to natural deficiency.

Quick Fact: Relief for Significant Deficiency Symptoms

Stilbestrol is commonly used to help with groups of symptoms that interfere with daily comfort, such as those related to significant estrogen deficiency, including symptoms related to heightened physiological activity (hot flashes) and symptoms related to inflammatory or irritative states (genitourinary atrophy).

Regulatory References

1. National Institutes of Health (NIH) Bookshelf overview

Who Can and Cannot Use Stilbestrol?

The population eligibility for Stilbestrol (Diethylstilbestrol or DES) is highly restrictive and defined by a strict set of absolute contraindications and limited approved uses, as documented by regulatory agencies.

Contraindicated Populations (Must Not Use)

Use of Stilbestrol is absolutely prohibited for certain groups:

• Pregnant Individuals: Contraindicated at any stage due to its classification as a known transplacental carcinogen and teratogen.
• Thromboembolic History: Individuals with active or a past history of thromboembolic disorders (e.g., DVT, pulmonary embolism, cerebral apoplexy).
• Cancer Status: Patients with known or suspected estrogen-dependent neoplasia, including breast carcinoma, except for specific palliative use in postmenopausal women.
• Liver Disease: Individuals with severe or active liver disease or undiagnosed abnormal genital bleeding.
• Children (Paediatric Population): The medicine should not be used in children.

Populations for Restricted/Conditional Use

Stilbestrol is approved only for specific conditions:

• Men with advanced progressive prostate carcinoma.
• Postmenopausal women with metastatic breast carcinoma or those requiring therapy for severe estrogen deficiency.

Use requires caution and is restricted in patients with pre-existing conditions like cardiac disease, renal disease, or diabetes due to the potential for fluid retention and metabolic effects.

Interactions with other medicines and products

Stilbestrol (Diethylstilbestrol) interactions are formally documented in regulatory sources and primarily involve alterations in metabolic clearance and pharmacodynamic outcomes.

Pharmacokinetic Interactions

Co-administration with hepatic enzyme inducers (e.g., phenobarbital, rifampin) may increase the metabolic clearance of Stilbestrol, leading to decreased plasma exposure. Conversely, co-administration with hepatic enzyme inhibitors (e.g., azole antifungals, macrolide antibiotics) may decrease Stilbestrol's clearance, which results in increased plasma concentrations.

Stilbestrol itself may inhibit the clearance of other drugs, resulting in increased plasma concentrations of co-administered agents like corticosteroids and cyclosporine, as stated in prescribing information.

Pharmacodynamic and Outcome Interactions

Stilbestrol can decrease the activity of anticoagulants (e.g., Warfarin) and may antagonize the therapeutic effects of antihypertensives and diuretics. Its hormonal action can also reduce glucose tolerance, potentially increasing the dosage requirement for antidiabetic agents like insulin.

Official labeling notes a specific interaction where Stilbestrol may interfere with the therapeutic effect of Tamoxifen. Furthermore, it is documented to affect laboratory tests by increasing thyroid hormone binding globulin (TBG), which must be accounted for when interpreting thyroid function results.

Stilbestrol is a non-steroidal estrogen receptor agonist. Its primary pharmacodynamic mechanism involves binding to and activating both the ERalpha and ERbeta receptors. This binding event elicits an estrogenic signal that initiates subsequent genomic and non-genomic signaling cascades. Intracellularly, Stilbestrol regulates the transcription of specific target genes in responsive tissues. This process modulates system-level physiology, including the suppression of FSH and LH release from the pituitary gland via the hypothalamic-pituitary axis. Furthermore, in bone tissue, the signaling events influence the delicate osteoblast/osteoclast balance. The action on the central axis also modulates neuronal activity related to thermoregulatory centers, directly influencing heat dissipation pathways.

How to Use Stilbestrol (Diethylstilbestrol)

Stilbestrol (Diethylstilbestrol or DES) is largely discontinued for human use in various regions, with current applications primarily focusing on veterinary medicine in specific jurisdictions. The instructions for use involve specific administration routes, dosing phases, and handling precautions.

Official Administration and Dosing

Procedural and Handling Requirements

Administration is generally permitted with or without food. In the event of a missed dose, the standard procedure is to take it as soon as remembered unless it is near the time for the next dose; doses are not to be doubled. Due to its classification as a hazardous substance, specific procedural conditions dictate that gloves must be worn when handling the tablets to prevent accidental exposure.

Research Evidence / Overview of Studies for Stilbestrol

Evidence for Hormone-Sensitive Conditions

Research has examined Stilbestrol for use in hormone-sensitive cancers, including advanced prostate cancer and, historically, metastatic breast cancer. Studies for prostate cancer examined outcomes such as Biochemical Response (PSA measurements) and overall survival, relying on foundational Randomized Controlled Trials (RCTs) and subsequent retrospective cohort studies. Historical studies for breast cancer reported measurements related to tumor responses and disease progression.

For symptoms of severe estrogen deficiency, such as hot flashes and atrophy, research measured Symptom Scores in various clinical trials and observational studies. Findings were consistent with the medicine's known action as an estrogenic compound. Evidence for conditions causing chronic absence of natural estrogen, like female hypogonadism, consists primarily of Clinical Observations and Historical Case Series.

Research Gaps and Uncertainty

A primary limitation of the Stilbestrol research base is the reliance on historical evidence for many of its uses, meaning the data applies only to the conditions under which they were conducted decades ago. Comparative evidence is lacking against most modern hormonal agents, which are now the preferred standard of care.

For several indications, study follow-up durations were short in many reports, meaning long-term patient outcomes are not fully established and long-term data are not well characterized. The evidence base for current, lower-dose applications often stems from smaller, less-controlled studies.

Key Studies & References

1. Current role of diethylstilbestrol in the management of advanced prostate cancer - UroToday
2. Diethylstilbestrol (DES) Exposure and Cancer - National Cancer Institute (NCI) Fact Sheet
3. Diethylstilbestrol (DES) Pregnancy Treatment: A Promising Widely Used Therapy with Unintended Adverse Consequences - AMA Journal of Ethics
4. Diethylstilbestrol - 15th Report on Carcinogens - NCBI Bookshelf
5. DES Case Study - Women and Health Research - NCBI Bookshelf (Veterans Administration Cooperative Urological Research Group (VACURG) context)

Common questions about Stilbestrol (FAQ)

Q: What is Stilbestrol used for?

A: Stilbestrol is a synthetic nonsteroidal estrogen. It was historically indicated for specific conditions requiring estrogen replacement therapy, such as symptoms of menopause and certain types of breast and prostate cancer. Its use has been largely discontinued due to the availability of safer alternatives.

Q: How does Stilbestrol work in the body?

A: Stilbestrol functions by binding to and activating estrogen receptors in various tissues. This imitates the biological actions of naturally occurring estrogen hormones, influencing processes in the reproductive system, skeletal system, and other organs.

Q: Is Stilbestrol still prescribed today?

A: Prescribing of Stilbestrol for pregnant women has been discontinued globally. For other historical uses, its general prescription has significantly decreased due to evidence of serious adverse effects and the development of alternative treatments with more favorable risk profiles. It is rarely used today, primarily only in specific, exceptional medical contexts.

Q: What should I know about Stilbestrol's history?

A: Stilbestrol gained attention when it was widely prescribed from the 1940s through the 1970s, including to pregnant individuals to prevent miscarriage. It was later linked to an increased risk of a rare type of vaginal cancer, clear cell adenocarcinoma, in the daughters (DES Daughters) of those who took it during pregnancy. This history highlights the importance of long-term safety monitoring.

Official Storage and Disposal Requirements

Storage Conditions and Protection

Stilbestrol (Diethylstilbestrol) must be stored in a dry, cool, and well-ventilated place with restricted access, such as a locked area. The official regulatory requirement is to store the product below 30 C and protect it from both light and freezing to maintain stability. The container must be kept tightly closed at all times.

Child Safety and Handling

As specified by regulatory labels, Stilbestrol must be stored strictly out of the sight and reach of children.

Disposal Procedures

Unused or expired Stilbestrol is classified as a regulated hazardous waste (U089) by the U.S. Environmental Protection Agency (EPA). Consequently, disposal must be managed through an approved waste disposal plant and must strictly adhere to local, regional, and national hazardous waste regulations. Release into the environment or emptying into drains is strictly prohibited.